Matinas Biopharma Holdings Inc
ASE:MTNB
Products, Strategic Combinations
Matinas Biopharma Announces Collaboration With National Institute Of Allergy And Infectious Diseases To Evaluate Oral Formulations Of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platfor
Published: 12/07/2020 11:50 GMT
Matinas Biopharma Holdings Inc (MTNB) - Matinas Biopharma Announces Collaboration With the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ Lnc Platform Delivery Technology.
Matinas Biopharma - Any Product Generated As a Part of Efforts by Matinas and Niaid Would Require a License From Gilead for Use of Remdesivir.
Matinas Biopharma - Any Product Generated As a Part of Efforts by Matinas and Niaid Would Require License From Matinas for Use of Lnc Formulation.
Matinas Biopharma - Any Product Generated As a Part of Efforts by Matinas and Niaid Would Require a License From Gilead for Use of Remdesivir.
Matinas Biopharma - Any Product Generated As a Part of Efforts by Matinas and Niaid Would Require License From Matinas for Use of Lnc Formulation.